The antiviral activities of tetherin

Current Topics in Microbiology and Immunology

Volumn 371, Issue , 2013, Pages 67-104

  Neil, Stuart J D ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESCRT I PROTEIN; ESCRT PROTEIN; MEMBRANE PROTEIN; NEF PROTEIN; PROTEIN K5; TETHERIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN; VIRUS PROTEIN; VPU PROTEIN; BST2 PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; LEUKOCYTE ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; CELL COMMUNICATION; CELLULAR DISTRIBUTION; CRYSTAL STRUCTURE; CYTOMEGALOVIRUS; DISEASE COURSE; EBOLA VIRUS; GENETIC VARIABILITY; HOST CELL; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2; IMMUNE RESPONSE; IMMUNOREGULATION; IN VIVO STUDY; INFLUENZA VIRUS A; LENTIVIRINAE; MAMMAL; NONHUMAN; PANDEMIC; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEFECT; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; SIMIAN IMMUNODEFICIENCY VIRUS; TISSUE DISTRIBUTION; TRANSCRIPTION REGULATION; UBIQUITINATION; VIRION; VIRUS CELL INTERACTION; VIRUS INFECTION; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TRANSMISSION; ANIMAL; IMMUNOLOGY; INNATE IMMUNITY; REVIEW; VIRUS;

ANIMALS; ANTIGENS, CD; GPI-LINKED PROTEINS; HUMANS; IMMUNITY, INNATE; VIRUSES;

EID: 84882373580     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-37765-5_3     Document Type: Article

References (168)

1. Abada P, Noble B, Cannon PM (2005) Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production. J Virol 79:3627-3638 (Pubitemid 40327951)
2. Agromayor M, Soler N, Caballe A, Kueck T, Freund SM, Allen MD et al (2012) The UBAP1 subunit of ESCRT-I interacts with ubiquitin via a SOUBA domain. Structure 20:414-428
3. Andrew AJ, Miyagi E, Kao S, Strebel K (2009) The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu. Retrovirology 6:80
4. Andrew AJ, Kao S, Strebel K (2011a) C-terminal hydrophobic region in human bone marrow stromal cell antigen 2 (BST-2)/tetherin protein functions as second transmembrane motif. J Biol Chem 286:39967-39981
5. Andrew AJ, Miyagi E, Strebel K (2011b) Differential effects of human immunodeficiency virus type 1 Vpu on the stability of BST-2/tetherin. J Virol 85:2611-2619
6. Arnaud F, Black SG, Murphy L, Griffiths DJ, Neil SJ, Spencer TE et al (2010) Interplay between ovine bone marrow stromal cell antigen 2/tetherin and endogenous retroviruses. J Virol 84:4415-4425
7. Barrett BS, Smith DS, Li SX, Guo K, Hasenkrug KJ, Santiago ML (2012) A single nucleotide polymorphism in tetherin promotes retrovirus restriction in vivo. PLoS Pathog 8:e1002596
8. Bartee E, McCormack A, Fruh K (2006) Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog 2:e107
9. Bego MG, Mercier J, Cohen EA (2012) Virus-activated interferon regulatory factor 7 upregulates expression of the interferon-regulated BST2 gene independently of interferon signaling. J Virol 86:3513-3527
10. Billcliff PG, Rollason R, Prior I, Owen DM, Gaus K, Banting G (2013) CD317/tetherin is an organiser of membrane microdomains. J Cell Sci [advancer online publication, 23378022]
11. Blasius AL, Giurisato E, Cella M, Schreiber RD, Shaw AS, Colonna M (2006) Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation. J Immunol 177:3260-3265 (Pubitemid 44277845)
12. Bolduan S, Votteler J, Lodermeyer V, Greiner T, Koppensteiner H, Schindler M et al (2011) Ion channel activity of HIV-1 Vpu is dispensable for counteraction of CD317. Virology 416:75-85
13. Boname JM, Lehner PJ (2011) What has the study of the K3 and K5 viral ubiquitin E3 ligases taught us about ubiquitin-mediated receptor regulation? Viruses 3:118-131
14. Boname JM, Thomas M, Stagg HR, Xu P, Peng J, Lehner PJ (2010) Efficient internalization of MHC I requires lysine-11 and lysine-63 mixed linkage polyubiquitin chains. Traffic 11:210-220
15. Bour S, Strebel K (1996) The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses. J Virol 70:8285-8300 (Pubitemid 26378403)
16. Bour S, Strebel K (2003) The HIV-1 Vpu protein: a multifunctional enhancer of viral particle release. Microbes Infect 5:1029-1039 (Pubitemid 36980856)
17. Bour S, Akari H, Miyagi E, Strebel K (2003) Naturally occurring amino acid substitutions in the HIV-2 ROD envelope glycoprotein regulate its ability to augment viral particle release. Virology 309:85-98 (Pubitemid 36506592)
18. Bruce EA, Abbink TE, Wise HM, Rollason R, Galao RP, Banting G et al (2012) Release of filamentous and spherical influenza A virus is not restricted by tetherin. J Gen Virol 93:963-969
19. Caillet M, Janvier K, Pelchen-Matthews A, Delcroix-Genete D, Camus G, Marsh M et al (2011) Rab7A is required for efficient production of infectious HIV-1. PLoS Pathog 7:e1002347
20. Cao W, Bover L, Cho M, Wen X, Hanabuchi S, Bao M et al (2009) Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. J Exp Med 206:1603-1614
21. Casartelli N, Sourisseau M, Feldmann J, Guivel-Benhassine F, Mallet A, Marcelin AG et al (2010) Tetherin restricts productive HIV-1 cell-to-cell transmission. PLoS Pathog 6:e1000955
22. Celestino M, Calistri A, Del Vecchio C, Salata C, Chiuppesi F, Pistello M et al (2012) Feline tetherin is characterized by a short N-terminal region and is counteracted by the feline immunodeficiency virus envelope glycoprotein. J Virol 86:6688-6700
23. Chu H, Wang JJ, Qi M, Yoon JJ, Chen X, Wen X et al (2012) Tetherin/BST-2 is essential for the formation of the intracellular virus-containing compartment in HIV-infected macrophages. Cell Host Microbe 12:360-372
24. Cocka LJ, Bates P (2012) Identification of alternatively translated tetherin isoforms with differing antiviral and signaling activities. PLoS Pathog 8:e1002931
25. Dietrich I, McMonagle EL, Petit SJ, Vijayakrishnan S, Logan N, Chan CN et al (2011) Feline tetherin efficiently restricts release of feline immunodeficiency virus but not spreading of infection. J Virol 85:5840-5852
26. Douglas JL, Viswanathan K, McCarroll MN, Gustin JK, Fruh K, Moses AV (2009) Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/tetherin via a {beta}TrCP-dependent mechanism. J Virol 83:7931-7947
27. Dube M, Roy BB, Guiot-Guillain P, Mercier J, Binette J, Leung G et al (2009) Suppression of tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network. J Virol 83:4574-4590
28. Dube M, Roy BB, Guiot-Guillain P, Binette J, Mercier J, Chiasson A et al (2010) Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog 6:e1000856
29. Dube M, Paquay C, Roy BB, Bego MG, Mercier J, Cohen EA (2011) HIV-1 Vpu antagonizes BST-2 by interfering mainly with the trafficking of newly synthesized BST-2 to the cell surface. Traffic 12:1714-1729
30. Duncan LM, Piper S, Dodd RB, Saville MK, Sanderson CM, Luzio JP et al (2006) Lysine-63-linked ubiquitination is required for endolysosomal degradation of class I molecules. EMBO J 25:1635-1645
31. Erikson E, Adam T, Schmidt S, Lehmann-Koch J, Over B, Goffinet C et al (2011) In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1.24/tetherin in humans. Proc Natl Acad Sci USA 108:13688-13693
32. Evans DT, Serra-Moreno R, Singh RK, Guatelli JC (2010) BST-2/tetherin: a new component of the innate immune response to enveloped viruses. Trends Microbiol 18:388-396
33. Fitzpatrick K, Skasko M, Deerinck TJ, Crum J, Ellisman MH, Guatelli J (2010) Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles. PLoS Pathog 6:e1000701
34. Fritz JV, Tibroni N, Keppler OT, Fackler OT (2012) HIV-1 Vpu's lipid raft association is dispensable for counteraction of the particle release restriction imposed by CD317/tetherin. Virology 424:33-44
35. Galao RP, Le Tortorec A, Pickering S, Kueck T, Neil SJ (2012) Innate sensing of HIV-1 assembly by tetherin induces NFkappaB-dependent proinflammatory responses. Cell Host Microbe 12:633-644
36. Ganem D (2006) KSHV infection and the pathogenesis of Kaposi's sarcoma. Annu Rev Pathol 1:273-296
37. Goffinet C, Allespach I, Homann S, Tervo HM, Habermann A, Rupp D et al (2009) HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe 5:285-297
38. Goffinet C, Homann S, Ambiel I, Tibroni N, Rupp D, Keppler OT et al (2010) Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 Vpu. J Virol 84:4089-4094
39. Gottlinger HG, Dorfman T, Cohen EA, Haseltine WA (1993) Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. Proc Natl Acad Sci USA 90:7381-7385 (Pubitemid 23222454)
40. Gotz N, Sauter D, Usmani SM, Fritz JV, Goffinet C, Heigele A et al (2012) Reacquisition of Nef-mediated tetherin antagonism in a single in vivo passage of HIV-1 through its original chimpanzee host. Cell Host Microbe 12:373-380
41. Grover JR, Llewellyn GN, Soheilian F, Nagashima K, Veatch SL, Ono A (2013) Roles played by capsid-dependent induction of membrane curvature and Gag-ESCRT interactions in tetherin recruitment to HIV-1 assembly sites. J Virol 87(8):4650-4664. doi:10.1128/JVI.03526-12. [Epub 2013 Feb 13]
42. Gummuluru S, Kinsey CM, Emerman M (2000) An in vitro rapid-turnover assay for human immunodeficiency virus type 1 replication selects for cell-to-cell spread of virus. J Virol 74:10882-10891 (Pubitemid 32223952)
43. Gupta RK, Hue S, Schaller T, Verschoor E, Pillay D, Towers GJ (2009a) Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS Pathog 5:e1000443
44. Gupta RK, Mlcochova P, Pelchen-Matthews A, Petit SJ, Mattiuzzo G, Pillay D et al (2009b) Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. Proc Natl Acad Sci USA 106:20889-20894
45. Gustin JK, Douglas JL, Bai Y, Moses AV (2012) Ubiquitination of BST-2 protein by HIV-1 Vpu protein does not require lysine, serine, or threonine residues within the BST-2 cytoplasmic domain. J Biol Chem 287:14837-14850
46. Hammonds J, Wang JJ, Yi H, Spearman P (2010) Immunoelectron microscopic evidence for tetherin/BST2 as the physical bridge between HIV-1 virions and the plasma membrane. PLoS Pathog 6:e1000749
47. Hammonds J, Ding L, Chu H, Geller K, Robbins A, Wang JJ et al (2012) The tetherin/BST-2 coiled-coil ectodomain mediates plasma membrane microdomain localization and restriction of particle release. J Virol 86:2259-2272
48. Harila K, Salminen A, Prior I, Hinkula J, Suomalainen M (2007) The Vpu-regulated endocytosis of HIV-1 Gag is clathrin-independent. Virology 369:299-308 (Pubitemid 350103595)
49. Hauser H, Lopez LA, Yang SJ, Oldenburg JE, Exline CM, Guatelli JC et al (2010) HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. Retrovirology 7:51
50. Hinz A, Miguet N, Natrajan G, Usami Y, Yamanaka H, Renesto P et al (2010) Structural basis of HIV-1 tethering to membranes by the BST-2/tetherin ectodomain. Cell Host Microbe 7:314-323
51. Homann S, Smith D, Little S, Richman D, Guatelli J (2011) Upregulation of BST-2/tetherin by HIV infection in vivo. J Virol 85:10659-10668
52. Ilinskaya A, Derse D, Hill S, Princler G, Heidecker G (2013) Cell-cell transmission allows human T-lymphotropic virus 1 to circumvent tetherin restriction. Virology 436:201-209
53. Ishido S, Wang C, Lee BS, Cohen GB, Jung JU (2000) Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins. J Virol 74:5300-5309 (Pubitemid 30313872)
54. Ishikawa J, Kaisho T, Tomizawa H, Lee BO, Kobune Y, Inazawa J et al (1995) Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth. Genomics 26:527-534
55. Iwabu Y, Fujita H, Kinomoto M, Kaneko K, Ishizaka Y, Tanaka Y et al (2009) HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes. J Biol Chem 284:35060-35072
56. Janvier K, Pelchen-Matthews A, Renaud JB, Caillet M, Marsh M, Berlioz-Torrent C (2011) The ESCRT-0 component HRS is required for HIV-1 Vpu-mediated BST-2/tetherin down-regulation. PLoS Pathog 7:e1001265
57. Janvier K, Roy N, Berlioz-Torrent C (2012) Role of the endosomal ESCRT machinery in HIV-1 Vpu-induced down-regulation of BST2/tetherin. Curr HIV Res 10:315-320
58. Jia B, Serra-Moreno R, Neidermyer W, Rahmberg A, Mackey J, Fofana IB et al (2009) Speciesspecific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog 5:e1000429
59. Jolly C, Booth NJ, Neil SJ (2010) Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells. J Virol 84:12185-12199
60. Jones PH, Mehta HV, Maric M, Roller RJ, Okeoma CM (2012) Bone marrow stromal cell antigen 2 (BST-2) restricts mouse mammary tumor virus (MMTV) replication in vivo. Retrovirology 9:10
61. Jouvenet N, Neil SJ, Zhadina M, Zang T, Kratovac Z, Lee Y et al (2009) Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J Virol 83:1837-1844
62. Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P (2009) Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci USA 106:2886-2891
63. Kelly BT, Owen DJ (2011) Endocytic sorting of transmembrane protein cargo. Curr Opin Cell Biol 23:404-412
64. Klimkait T, Strebel K, Hoggan MD, Martin MA, Orenstein JM (1990) The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J Virol 64:621-629 (Pubitemid 20032674)
65. Kobayashi T, Ode H, Yoshida T, Sato K, Gee P, Yamamoto SP et al (2011) Identification of amino acids in the human tetherin transmembrane domain responsible for HIV-1 Vpu interaction and susceptibility. J Virol 85:932-945
66. Kong WS, Irie T, Yoshida A, Kawabata R, Kadoi T, Sakaguchi T (2012) Inhibition of virus-like particle release of Sendai virus and Nipah virus, but not that of mumps virus, by tetherin/CD317/BST-2. Hiroshima J Med Sci 61:59-67
67. Kueck T, Neil SJ (2012) A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction. PLoS Pathog 8:e1002609
68. Kuhl BD, Sloan RD, Donahue DA, Bar-Magen T, Liang C, Wainberg MA (2010) Tetherin restricts direct cell-to-cell infection of HIV-1. Retrovirology 7:115
69. Kuhl A, Banning C, Marzi A, Votteler J, Steffen I, Bertram S et al (2011) The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin. J Infect Dis 204(Suppl 3):S850-S860
70. Kupzig S, Korolchuk V, Rollason R, Sugden A, Wilde A, Banting G (2003) Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 4:694-709 (Pubitemid 37168591)
71. Laplana M, Caruz A, Pineda JA, Puig T, Fibla J (2013) Association of BST-2 gene variants with HIV disease progression underscores the role of BST-2 in HIV type 1 infection. J Infect Dis 207:411-419
72. Lau D, Kwan W, Guatelli J (2011) Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogens. J Virol 85:9834-9846
73. Le Clerc S, Coulonges C, Delaneau O, Van Manen D, Herbeck JT, Limou S et al (2011) Screening low-frequency SNPS from genome-wide association study reveals a new risk allele for progression to AIDS. J Acquir Immune Defic Syndr 56:279-284
74. Le Tortorec A, Neil SJ (2009) Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. J Virol 83:11966-11978
75. Le Tortorec A, Willey S, Neil SJ (2011) Antiviral inhibition of enveloped virus release by tetherin/BST-2: action and counteraction. Viruses 3:520-540
76. Lehmann M, Rocha S, Mangeat B, Blanchet F, Uji IH, Hofkens J et al (2011) Quantitative multicolor super-resolution microscopy reveals tetherin HIV-1 interaction. PLoS Pathog 7:e1002456
77. Lehner PJ, Hoer S, Dodd R, Duncan LM (2005) Downregulation of cell surface receptors by the K3 family of viral and cellular ubiquitin E3 ligases. Immunol Rev 207:112-125 (Pubitemid 41415012)
78. Lepelley A, Louis S, Sourisseau M, Law HK, Pothlichet J, Schilte C et al (2011) Innate sensing of HIV-infected cells. PLoS Pathog 7:e1001284
79. Liberatore RA, Bieniasz PD (2011) Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo. Proc Natl Acad Sci USA 108:18097-18101
80. Lim ES, Malik HS, Emerman M (2010) Ancient adaptive evolution of tetherin shaped the functions of Vpu and Nef in human immunodeficiency virus and primate lentiviruses. J Virol 84:7124-7134
81. Lindwasser OW, Smith WJ, Chaudhuri R, Yang P, Hurley JH, Bonifacino JS (2008) A diacidic motif in human immunodeficiency virus type 1 Nef is a novel determinant of binding to AP-2. J Virol 82:1166-1174
82. Lopez LA, Yang SJ, Hauser H, Exline CM, Haworth KG, Oldenburg J et al (2010) Ebola virus glycoprotein counteracts BST-2/tetherin restriction in a sequence-independent manner that does not require tetherin surface removal. J Virol 84:7243-7255
83. Lopez LA, Yang SJ, Exline CM, Rengarajan S, Haworth KG, Cannon PM (2012) Anti-tetherin activities of HIV-1 Vpu and Ebola virus glycoprotein do not involve removal of tetherin from lipid rafts. J Virol 86:5467-5480
84. Loschko J, Schlitzer A, Dudziak D, Drexler I, Sandholzer N, Bourquin C et al (2011) Antigen delivery to plasmacytoid dendritic cells via BST2 induces protective T cell-mediated immunity. J Immunol 186:6718-6725
85. Magadan JG, Bonifacino JS (2012) Transmembrane domain determinants of CD4 downregulation by HIV-1 Vpu. J Virol 86:757-772
86. Magadan JG, Perez-Victoria FJ, Sougrat R, Ye Y, Strebel K, Bonifacino JS (2010) Multilayered mechanism of CD4 downregulation by HIV-1 Vpu involving distinct ER retention and ERAD targeting steps. PLoS Pathog 6:e1000869
87. Mangeat B, Gers-Huber G, Lehmann M, Zufferey M, Luban J, Piguet V (2009) HIV-1 Vpu neutralizes the antiviral factor tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog 5:e1000574
88. Mangeat B, Cavagliotti L, Lehmann M, Gers-Huber G, Kaur I, Thomas Y et al (2012) Influenza virus partially counteracts restriction imposed by tetherin/BST-2. J Biol Chem 287:22015-22029
89. Mansouri M, Viswanathan K, Douglas JL, Hines J, Gustin J, Moses AV et al (2009) Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi's sarcoma-associated herpesvirus. J Virol 83:9672-9681
90. Margottin F, Bour SP, Durand H, Selig L, Benichou S, Richard V et al (1998) A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell 1:565-574 (Pubitemid 128374692)
91. Martin-Serrano J, Neil SJ (2011) Host factors involved in retroviral budding and release. Nat Rev Microbiol 9:519-531
92. Matsuda A, Suzuki Y, Honda G, Muramatsu S, Matsuzaki O, Nagano Y et al (2003) Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways. Oncogene 22:3307-3318 (Pubitemid 36712943)
93. McNatt MW, Zang T, Hatziioannou T, Bartlett M, Fofana IB, Johnson WE et al (2009) Speciesspecific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog 5:e1000300
94. Mettenleiter TC, Klupp BG, Granzow H (2006) Herpesvirus assembly: a tale of two membranes. Curr Opin Microbiol 9:423-429 (Pubitemid 44108724)
95. Mitchell RS, Katsura C, Skasko MA, Fitzpatrick K, Lau D, Ruiz A et al (2009) Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking. PLoS Pathog 5:e1000450
96. Miyakawa K, Ryo A, Murakami T, Ohba K, Yamaoka S, Fukuda M et al (2009) BCA2/Rabring7 promotes tetherin-dependent HIV-1 restriction. PLoS Pathog 5:e1000700
97. Miyakawa K, Sawasaki T, Matsunaga S, Tokarev A, Quinn G, Kimura H et al (2012) Interferoninduced SCYL2 limits release of HIV-1 by triggering PP2A-mediated dephosphorylation of the viral protein Vpu. Sci Signal 5:ra73
98. Moffat JM, Segura E, Khoury G, Caminschi I, Cameron PU, Lewin SR et al. (2013) Targeting antigen to bone marrow stromal cell-2 expressed by conventional and plasmacytoid dendritic cells elicits efficient antigen presentation. Eur J Immunol 43(3):595-605. doi:10.1002/eji.201242799. [Epub 2013 Feb 6]
99. Neil S, Bieniasz P (2009) Human immunodeficiency virus, restriction factors, and interferon. J Interferon Cytokine Res 29:569-580
100. Neil SJ, Eastman SW, Jouvenet N, Bieniasz PD (2006) HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. PLoS Pathog 2:e39
101. Neil SJ, Sandrin V, Sundquist WI, Bieniasz PD (2007) An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe 2:193-203 (Pubitemid 47355204)
102. Neil SJ, Zang T, Bieniasz PD (2008) Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451:425-430 (Pubitemid 351158893)
103. Noble B, Abada P, Nunez-Iglesias J, Cannon PM (2006) Recruitment of the adaptor protein 2 complex by the human immunodeficiency virus type 2 envelope protein is necessary for high levels of virus release. J Virol 80:2924-2932 (Pubitemid 43346387)
104. Ohtomo T, Sugamata Y, Ozaki Y, Ono K, Yoshimura Y, Kawai S et al (1999) Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem Biophys Res Commun 258:583-591 (Pubitemid 29290312)
105. Pais-Correia AM, Sachse M, Guadagnini S, Robbiati V, Lasserre R, Gessain A et al (2010) Biofilm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell transmission at virological synapses. Nat Med 16:83-89
106. Pan XB, Han JC, Cong X, Wei L (2012) BST2/tetherin inhibits dengue virus release from human hepatoma cells. PLoS ONE 7:e51033
107. Pardieu C, Vigan R, Wilson SJ, Calvi A, Zang T, Bieniasz P et al (2010) The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin. PLoS Pathog 6:e1000843
108. Park SH, Mrse AA, Nevzorov AA, Mesleh MF, Oblatt-Montal M, Montal M et al (2003) Threedimensional structure of the channel-forming trans-membrane domain of virus protein "u" (Vpu) from HIV-1. J Mol Biol 333:409-424 (Pubitemid 37188581)
109. Patel MR, Emerman M, Malik HS (2011) Paleovirology-ghosts and gifts of viruses past. Curr Opin Virol 1:304-309
110. Perez-Caballero D, Zang T, Ebrahimi A, McNatt MW, Gregory DA, Johnson MC et al (2009) Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 139:499-511
111. Petit SJ, Blondeau C, Towers GJ (2011) Analysis of the human immunodeficiency virus type 1 M group Vpu domains involved in antagonizing tetherin. J Gen Virol 92:2937-2948
112. Pillai SK, Abdel-Mohsen M, Guatelli J, Skasko M, Monto A, Fujimoto K et al (2012) Role of retroviral restriction factors in the interferon-alpha- mediated suppression of HIV-1 in vivo. Proc Natl Acad Sci USA 109:3035-3040
113. Radoshitzky SR, Dong L, Chi X, Clester JC, Retterer C, Spurgers K et al (2010) Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin. J Virol 84:10569-10580
114. Rollason R, Korolchuk V, Hamilton C, Schu P, Banting G (2007) Clathrin-mediated endocytosis of a lipid-raft-associated protein is mediated through a dual tyrosine motif. J Cell Sci 120:3850-3858 (Pubitemid 350187366)
115. Rollason R, Korolchuk V, Hamilton C, Jepson M, Banting G (2009) A CD317/tetherin-RICH2 complex plays a critical role in the organization of the subapical actin cytoskeleton in polarized epithelial cells. J Cell Biol 184:721-736
116. Ruiz A, Hill MS, Schmitt K, Guatelli J, Stephens EB (2008) Requirements of the membrane proximal tyrosine and dileucine-based sorting signals for efficient transport of the subtype C Vpu protein to the plasma membrane and in virus release. Virology 378:58-68
117. Sakuma T, Noda T, Urata S, Kawaoka Y, Yasuda J (2009) Inhibition of Lassa and Marburg virus production by tetherin. J Virol 83:2382-2385
118. Sauter D, Kirchhoff F (2011) Tetherin antagonism by primate lentiviral nef proteins. Curr HIV Res 9:514-523
119. Sauter D, Schindler M, Specht A, Landford WN, Munch J, Kim KA et al (2009) Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 6:409-421
120. Sauter D, Specht A, Kirchhoff F (2010) Tetherin: holding on and letting go. Cell 141:392-398
121. Sauter D, Hue S, Petit SJ, Plantier JC, Towers GJ, Kirchhoff F et al (2011a) HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef. Retrovirology 8:103
122. Sauter D, Vogl M, Kirchhoff F (2011b) Ancient origin of a deletion in human BST2/tetherin that confers protection against viral zoonoses. Hum Mutat 32:1243-1245
123. Sauter D, Unterweger D, Vogl M, Usmani SM, Heigele A, Kluge SF et al (2012) Human tetherin exerts strong selection pressure on the HIV-1 group N Vpu protein. PLoS Pathog 8:e1003093
124. Schindler M, Rajan D, Banning C, Wimmer P, Koppensteiner H, Iwanski A et al (2010) Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages, but not in ex vivo human lymphoid tissue. Retrovirology 7:1.
125. Schmidt S, Fritz JV, Bitzegeio J, Fackler OT, Keppler OT (2011) HIV-1 Vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor CD317/tetherin to overcome the virion release restriction. MBio 2:e00036-11
126. Schubert U, Strebel K (1994) Differential activities of the human immunodeficiency virus type 1-encoded Vpu protein are regulated by phosphorylation and occur in different cellular compartments. J Virol 68:2260-2271
127. Schubert U, Clouse KA, Strebel K (1995) Augmentation of virus secretion by the human immunodeficiency virus type 1 Vpu protein is cell type independent and occurs in cultured human primary macrophages and lymphocytes. J Virol 69:7699-7711
128. Schubert U, Ferrer-Montiel AV, Oblatt-Montal M, Henklein P, Strebel K, Montal M (1996) Identification of an ion channel activity of the Vpu transmembrane domain and its involvement in the regulation of virus release from HIV-1-infected cells. FEBS Lett 398:12-18 (Pubitemid 26400334)
129. Schubert HL, Zhai Q, Sandrin V, Eckert DM, Garcia-Maya M, Saul L et al (2010) Structural and functional studies on the extracellular domain of BST2/tetherin in reduced and oxidized conformations. Proc Natl Acad Sci USA 107:17951-17956
130. Serra-Moreno R, Jia B, Breed M, Alvarez X, Evans DT (2011) Compensatory changes in the cytoplasmic tail of gp41 confer resistance to tetherin/BST-2 in a pathogenic nef-deleted SIV. Cell Host Microbe 9:46-57
131. Sharp PM, Hahn BH (2011) Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med 1:a006841
132. Sherer NM, Lehmann MJ, Jimenez-Soto LF, Horensavitz C, Pypaert M, Mothes W (2007) Retroviruses can establish filopodial bridges for efficient cell-to-cell transmission. Nat Cell Biol 9:310-315 (Pubitemid 46344610)
133. Skasko M, Tokarev A, Chen CC, Fischer WB, Pillai SK, Guatelli J (2011) BST-2 is rapidly down-regulated from the cell surface by the HIV-1 protein Vpu: evidence for a post-ER mechanism of Vpu-action. Virology 411:65-77
134. Skasko M, Wang Y, Tian Y, Tokarev A, Munguia J, Ruiz A et al (2012) HIV-1 Vpu protein antagonizes innate restriction factor BST-2 via lipid-embedded helix-helix interactions. J Biol Chem 287:58-67
135. Skaug B, Jiang X, Chen ZJ (2009) The role of ubiquitin in NF-kappaB regulatory pathways. Annu Rev Biochem 78:769-796
136. Sliva K, Resch T, Kraus B, Goffinet C, Keppler OT, Schnierle BS (2012) The cellular antiviral restriction factor tetherin does not inhibit poxviral replication. J Virol 86:1893-1896
137. Stefani F, Zhang L, Taylor S, Donovan J, Rollinson S, Doyotte A et al (2011) UBAP1 is a component of an endosome-specific ESCRT-I complex that is essential for MVB sorting. Curr Biol 21:1245-1250
138. St-Germain JR, Taylor P, Tong J, Jin LL, Nikolic A, Stewart II et al (2009) Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition. Proc Natl Acad Sci USA 106:20127-20132
139. Strebel K, Klimkait T, Maldarelli F, Martin MA (1989) Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein. J Virol 63:3784-3791 (Pubitemid 19205450)
140. Swiecki M, Scheaffer SM, Allaire M, Fremont DH, Colonna M, Brett TJ (2011) Structural and biophysical analysis of BST-2/tetherin ectodomains reveals an evolutionary conserved design to inhibit virus release. J Biol Chem 286:2987-2997
141. Swiecki M, Wang Y, Gilfillan S, Lenschow DJ, Colonna M (2012) Cutting edge: paradoxical roles of BST2/tetherin in promoting type I IFN response and viral infection. J Immunol 188:2488-2492
142. Swiecki M, Omattage NS, Brett TJ (2013) BST-2/tetherin: Structural biology, viral antagonism, and immunobiology of a potent host antiviral factor. Mol Immunol 54:132-139
143. Takeuchi O, Akira S (2010) Pattern recognition receptors and inflammation. Cell 140:805-820
144. Tavano B, Galao RP, Graham DR, Neil SJ, Aquino VN, Fuchs D et al (2013) Ig-like Transcript 7, but Not Bone Marrow Stromal Cell Antigen 2 (Also Known as HM1.24, tetherin, or CD317), Modulates Plasmacytoid Dendritic Cell Function in Primary Human Blood Leukocytes. J Immunol 190(6):2622-2630
145. Tervo HM, Homann S, Ambiel I, Fritz JV, Fackler OT, Keppler OT (2011) beta-TrCP is dispensable for Vpu's ability to overcome the CD317/tetherin- imposed restriction to HIV-1 release. Retrovirology 8:9
146. Terwilliger EF, Cohen EA, Lu YC, Sodroski JG, Haseltine WA (1989) Functional role of human immunodeficiency virus type 1 vpu. Proc Natl Acad Sci USA 86:5163-5167 (Pubitemid 19182254)
147. Tokarev A, Guatelli J (2011) Misdirection of membrane trafficking by HIV-1 Vpu and Nef: Keys to viral virulence and persistence. Cell Logist 1:90-102
148. Tokarev AA, Munguia J, Guatelli JC (2011) Serine-threonine ubiquitination mediates downregulation of BST-2/tetherin and relief of restricted virion release by HIV-1 Vpu. J Virol 85:51-63
149. Tokarev A, Suarez M, Kwan W, Fitzpatrick K, Singh R, Guatelli J (2013) Stimulation of NFkappaB activity by the HIV restriction factor BST2. J Virol 87:2046-2057
150. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC et al (2008) The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3:245-252 (Pubitemid 351494713)
151. Varthakavi V, Smith RM, Bour SP, Strebel K, Spearman P (2003) Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. Proc Natl Acad Sci USA 100:15154-15159 (Pubitemid 37518032)
152. Varthakavi V, Smith RM, Martin KL, Derdowski A, Lapierre LA, Goldenring JR et al (2006) The pericentriolar recycling endosome plays a key role in Vpu-mediated enhancement of HIV-1 particle release. Traffic 7:298-307 (Pubitemid 43323957)
153. Vigan R, Neil SJ (2010) Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein. J Virol 84:12958-12970
154. Vigan R, Neil SJ (2011) Separable determinants of subcellular localization and interaction account for the inability of group O HIV-1 Vpu to counteract tetherin. J Virol 85:9737-9748
155. Viswanathan K, Smith MS, Malouli D, Mansouri M, Nelson JA, Fruh K (2011) BST2/tetherin enhances entry of human cytomegalovirus. PLoS Pathog 7:e1002332
156. Watanabe R, Leser GP, Lamb RA (2011) Influenza virus is not restricted by tetherin whereas influenza VLP production is restricted by tetherin. Virology 417:50-56
157. Weidner JM, Jiang D, Pan XB, Chang J, Block TM, Guo JT (2010) Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J Virol 84:12646-12657
158. Weissenhorn W, Miguet N, Aschman N, Renesto P, Usami Y, Gottlinger HG (2012) Structural basis of tetherin function. Curr HIV Res 10:298-306
159. Winkler M, Bertram S, Gnirss K, Nehlmeier I, Gawanbacht A, Kirchhoff F et al (2012) Influenza A virus does not encode a tetherin antagonist with Vpu-like activity and induces IFNdependent tetherin expression in infected cells. PLoS ONE 7:e43337
160. Yang H, Wang J, Jia X, McNatt MW, Zang T, Pan B et al (2010a) Structural insight into the mechanisms of enveloped virus tethering by tetherin. Proc Natl Acad Sci USA 107:18428-18432
161. Yang SJ, Lopez LA, Hauser H, Exline CM, Haworth KG, Cannon PM (2010b) Anti-tetherin activities in Vpu-expressing primate lentiviruses. Retrovirology 7:13
162. Yang SJ, Lopez LA, Exline CM, Haworth KG, Cannon PM (2011) Lack of adaptation to human tetherin in HIV-1 group O and P. Retrovirology 8:78
163. Yao XJ, Gottlinger H, Haseltine WA, Cohen EA (1992) Envelope glycoprotein and CD4 independence of vpu-facilitated human immunodeficiency virus type 1 capsid export. J Virol 66:5119-5126
164. Yondola MA, Fernandes F, Belicha-Villanueva A, Uccelini M, Gao Q, Carter C et al (2011) Budding capability of the influenza virus neuraminidase can be modulated by tetherin. J Virol 85:2480-2491
165. Yu P, Lubben W, Slomka H, Gebler J, Konert M, Cai C et al (2012) Nucleic acid-sensing Tolllike receptors are essential for the control of endogenous retrovirus viremia and ERVinduced tumors. Immunity 37:867-879
166. Zhang F, Wilson SJ, Landford WC, Virgen B, Gregory D, Johnson MC et al (2009) Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 6:54-67
167. Zhang F, Landford WN, Ng M, McNatt MW, Bieniasz PD, Hatziioannou T (2011) SIV Nef proteins recruit the AP-2 complex to antagonize tetherin and facilitate virion release. PLoS Pathog 7:e1002039
168. Zhong P, Agosto LM, Ilinskaya A, Dorjbal B, Truong R, Derse D et al (2013) Cell-to-cell transmission can overcome multiple donor and target cell barriers imposed on cell-free HIV. PLoS ONE 8:e53138